Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sagimet Biosciences, Inc. Class A (SGMT – ...

Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Perfect Corp. (NYSE: PERF), a global leader in beauty and fashion tech solutions, today announced the successful closing of its acquisition of Wannaby Inc., initially announced last month. This ...

CAMBRIDGE, Mass. & SALISBURY, England, January 08, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy recommendation. Analyst Price Forecast Suggests 224.00% Upside As of ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...